

Hummingbird Bioscience opens research facilities at Singapore Science Park

26 September 2022 | News

Bolstering in-house capabilities with new facilities



Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, has announced the official opening of its office and research facilities at the Singapore Science Park.

Deputy Prime Minister and Coordinating Minister for Economic Policies Heng Swee Keat officiated the opening ceremony at The Galen on 23rd September 2022. Located at The Galen and The Aries buildings, Hummingbird Bioscience's 40,000 sq. ft. space holds more than 10 state-of-the-art laboratories integrated with office space.

Piers Ingram, PhD, Chief Executive Officer and Co-founder of Hummingbird Bioscience said, "The Hummingbird Bioscience team has grown to a current headcount of 150 responsible for the full range of drug discovery and development activities from target validation, antibody discovery, bioinformatics to clinical development. We look forward to welcoming more talented teammates at our new location."

Enterprise Singapore (EnterpriseSG) has supported Hummingbird Bioscience closely on its growth, including the development of its platform technology. SEEDS Capital, the investment arm of EnterpriseSG, has also co-invested in the company.

The pharmacology, mass spectrometry, analytical science, production, genomics, discovery, engineering, and microbiology labs will further enable the Hummingbird Bioscience team to accelerate its biotherapeutics research. Integrated with office space, the proximity allows for a collaborative environment across multiple disciplines.